Dr Matthew Lunning discusses the potential of CAR T cell therapy for high-risk patients.
Dr Philippe Moreau discusses the patient selection process for CAR T cell therapy.
Dr Pere Barba discusses how patients may be candidates for CAR T cell therapy despite ineligibility for stem cell transplantation.
Dr Hermann Einsele discusses the variability of T cell health.
Dr Tanya Siddiqi describes the association of treatment-related toxicities with disease severity and CAR T cell activity.
Dr Ulrich Jäger discusses the importance of explaining therapeutic risks and benefits to patients and caregivers.
Back to top